ABOUT
    ABOUT US
    LEADERSHIP
        Executive Team
    MILESTONE
PRODUCT
    ALL
    Iron Deficiency Anemia
    Emergency Care
    Respiratory
PIPELINE
    PIPELINE
        Respiratory
        Pain Management
        Emergency Care
        Iron Deficiency Anemia
PARTNERSHIP
NEWS
    ALL
    Company News
        Strategic Cooperation Agreement with SHAPHAR
        Nuance Pharma advances Rare Disease R&D with CORD
        优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
        优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
        优锐医药受邀出席中关村肾病血液净化创新联盟 “峥嵘五年 再续华章” 五周年庆典
        优锐医药恩塞芬汀中国III期临床试验 全国研究者会顺利召开
        优锐医药助力2023中国医疗健康峰会
        Nuance Pharma Attended The 3rd BioCentury-BayHelix East-West Biopharma Summit in Singapore
    Media
        Nuance Pharma Closes Series D Financing
        Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
        Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
        Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
        Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
        IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
        专访优锐医药：呼吸精品特药领域，如何打造现金“造血”教科书？
        Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
        优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
        Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
        US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
        PharmaBoardroom Interview with Nuance Pharma founder & CEO Mark Lotter
        Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD
        Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
        Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
        Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
        Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
        Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
        Forge Ahead with a New Chapter: Nuance Pharma Beijing Headquarters Grand Opening Ceremony Celebrated in Changping
    Partner News
        Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
        Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
        Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
        Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
        Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
        Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
        Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
INVESTOR
CAREER
    PROFILE
    OPEN POSITION
        ALL
        R&D
CONTACT
    Report an Adverse Event